MolGraph
CompoundsDocumentationComplianceAbout
MolGraph

Research chemical sourcing and molecular building block RFQ workflows.

MolGraph is operated by Tessorix Inc.

support@molgraph.com

Products are intended for laboratory research use only and are not for human or veterinary use.

Compounds

  • Compound catalog
  • CAS Search

Company

  • About
  • Contact

Documentation

  • Quality Documentation
  • SDS Disclaimer

Compliance

  • Compliance

Legal

  • Terms
  • Privacy

Copyright © 2026 MolGraph. All Rights Reserved.

Home/Compounds/CAS 124858-35-1
Formula C19H21FN2O4MW 360.4Research-use catalog entryCOA/SDS by request

Nadifloxacin

CAS Number: 124858-35-1

Sourcing & RFQ

Submit an RFQ to review pricing, availability, lead time, pack size, purity, COA, and supplier SDS for this catalog entry.

Available options

Available Options

Package
1 g
Purity
98%
Price
Request review
Availability
Shipping review required
Delivery
Shipping review required
Package
1 mg
Purity
98%
Price
Request review
Availability
Shipping review required
Delivery
Shipping review required
Package
100 mg
Purity
98%
Price
Request review
Availability
Shipping review required
Delivery
Shipping review required
Package
250 mg
Purity
98%
Price
Request review
Availability
Shipping review required
Delivery
Shipping review required
Package
5 g
Purity
98%
Price
Request review
Availability
Shipping review required
Delivery
Shipping review required
Package
50 mg
Purity
98%
Price
Request review
Availability
Shipping review required
Delivery
Shipping review required

Shipping review is required before pricing or stock can be confirmed publicly. Shipping, duties, and documentation fees are confirmed before order acceptance.

Loading RDKit molecule structure...
InChIKey: JYJTVFIEFKZWCJ-UHFFFAOYSA-NC19H21FN2O4 | MW 360.4

Chemical Absolute Identifiers

CAS Number

124858-35-1

PubChem CID

4410

Molecular Formula

C19H21FN2O4

Molecular Weight

360.4 g/mol

Exact Mass

360.148535

InChIKey

JYJTVFIEFKZWCJ-UHFFFAOYSA-N

IUPAC Name

7-fluoro-8-(4-hydroxypiperidin-1-yl)-12-methyl-4-oxo-1-azatricyclo[7.3.1.05,13]trideca-2,5,7,9(13)-tetraene-3-carboxylic acid

SMILES String

CC1CCC2=C3N1C=C(C(=O)C3=CC(=C2N4CCC(CC4)O)F)C(=O)O

Physical Properties

No physical property values available.

Properties are provided as catalog reference data and may be confirmed through supplier documentation when required.

Catalog Facts

Structural features

Nadifloxacin (CAS 124858-35-1) is listed in the Pharmaceutical Intermediates portfolio, with molecular formula C19H21FN2O4 and molecular weight 360. 40 g/mol.

Sourcing context

Catalog reference for RFQ preparation, supplier confirmation, and research chemical sourcing review.

Research use context

Intended for research-stage medicinal chemistry and intermediate synthesis workflows; structure-derived tags include nitrogen-containing heterocycle.

Documentation needs

COA/SDS status, availability, lead time, pack size, and shipment documentation can be confirmed during quotation.

Applications & Classification

Pharmaceutical Intermediate ResearchResearch intermediateCustom synthesis building blockPharmaceutical intermediate researchResearch chemical sourcingCustom synthesis and catalog availability reviewCOA, SDS, pricing, and fulfillment workflow
Biological target reference

ChEMBL reports experimental activity evidence for: 5-hydroxytryptamine receptor 1A (Homo sapiens) — 2 assays; 5-hydroxytryptamine receptor 2A (Homo sapiens) — 2 assays; 5-hydroxytryptamine receptor 2B (Homo sapiens) — 2 assays; Alpha-1A adrenergic receptor (Homo sapiens) — 2 assays; Alpha-2A adrenergic receptor (Homo sapiens) — 2 assays. These records describe research assays and do not establish therapeutic efficacy or clinical use.

5-hydroxytryptamine receptor 1A

Homo sapiens · SINGLE PROTEIN · 2 qualifying assays · 1 documents

Experimental evidence source: ChEMBL

5-hydroxytryptamine receptor 2A

Homo sapiens · SINGLE PROTEIN · 2 qualifying assays · 1 documents

Experimental evidence source: ChEMBL

5-hydroxytryptamine receptor 2B

Homo sapiens · SINGLE PROTEIN · 2 qualifying assays · 1 documents

Experimental evidence source: ChEMBL

Alpha-1A adrenergic receptor

Homo sapiens · SINGLE PROTEIN · 2 qualifying assays · 1 documents

Experimental evidence source: ChEMBL

Alpha-2A adrenergic receptor

Homo sapiens · SINGLE PROTEIN · 2 qualifying assays · 1 documents

Experimental evidence source: ChEMBL

Safety & Handling

Safety and handling reference content is available through documentation requests.

For supplier-issued SDS, request documentation before handling, storage, shipment, or procurement decisions.

Preliminary Safety Reference

For supplier-issued SDS or COA, submit a documentation request.

Safety Reference / SDS Request

Names & Synonyms / External Identifiers

Chemical Name

Nadifloxacin

Names & Synonyms

jinofloxacinAcuatimNadifloxacineNadixaOpc 7251
Show all synonyms
NadifloxacinoNadifloxacinumNDFX1H,5H-Benzo[ij]quinolizine-2-carboxylic acid, 9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-1H,5H-Benzo(ij)quinolizine-2-carboxylic acid, 9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-, (+-)-1H,5H-Benzo(ij)quinolizine-2-carboxylic acid, 9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-7-fluoro-8-(4-hydroxypiperidin-1-yl)-12-methyl-4-oxo-1-azatricyclo(7.3.1.05,13)trideca-2,5,7,9(13)-tetraene-3-carboxylic acid9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidyl)-5-methyl-1-oxo-1H,5H-benzo(i,j)quinolizine-2-carboxylic acid9-fluoro-8-(4-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1,5,6,7-tetrahydropyrido[3,2,1-ij]quinoline-2-carboxylic acid9-fluoro-8-(4-hydroxypiperidin-1-yl)-5-methyl-1-oxo-6,7-dihydro-1H,5H-pyrido[3,2,1-ij]quinoline-2-carboxylic acidS-NadifloxacinNadifloxacine [INN-French]Nadifloxacinum [INN-Latin]Nadifloxacino [INN-Spanish]
External Identifiers
EC NUMBER: 638-863-6DSSTOX SUBSTANCE ID: DTXSID5046483CHEMBL ID: CHEMBL363449CHEBI ID: CHEBI:31889UNII: 6CL9Y5YZEQDRUGBANK ID: DB12447KEGG ID: D01147METABOLOMICS WORKBENCH ID: 144343NCI THESAURUS CODE: C166927WIKIDATA ID: Q426605
Experimental Spectrum References
ATR-IR Spectra — Forensic Spectral ResearchRaman Spectra — Forensic Spectral Research
Literature & Patent References
DOI 10.1016/j.isci.2024.108907Identification and evaluation of small-molecule inhibitors against the dNTPase SAMHD1 via a comprehensive screening funnelPMID 38318365Identification and evaluation of small-molecule inhibitors against the dNTPase SAMHD1 via a comprehensive screening funnelDOI 10.1038/s41467-023-40064-9A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.PMID 37468498A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.DOI 10.6019/CHEMBL4651402Screening of ~5500 FDA-approved drugs and clinical candidates for anti-SARS-CoV-2 activityDOI 10.6019/CHEMBL4808148HDAC6 screening dataset using tau-based substrate in an enzymatic assay yields selective inhibitors and activatorsDOI 10.1101/2020.04.03.023846In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replicationDOI 10.1101/2020.04.21.054387Identification of potential treatments for COVID-19 through artificial intelligence-enabled phenomic analysis of human cells infected with SARS-CoV-2

Documentation & Compliance Facts

Compliance Facts

Shipment review: Required

Documentation available by request

Certificate of Analysis (COA): By request

Supplier Safety Data Sheet (SDS): By request

Purity and pack size confirmation: By request

Availability and lead time review: Confirmed by RFQ

Shipment documentation review: By request

For supplier-issued documentation by request, use the RFQ actions on this page.Review preliminary safety reference

What happens after RFQ

  1. 1We review the CAS identity, quantity, and documentation request.
  2. 2We check sourcing options, supplier availability, COA/SDS, purity, pack size, and lead time.
  3. 3We review destination and shipment documentation needs when applicable.
  4. 4We follow up with a quotation or clarification request.

Text Reference Cues

Show non-linked catalog cues

Non-public related references

GatifloxacinCAS 112811-59-3
Gatifloxacin hydrochlorideCAS 121577-32-0
Gatifloxacin sesquihydrateCAS 180200-66-2
FleroxacinCAS 79660-72-3
Besifloxacin HydrochlorideCAS 405165-61-9

Non-public references are shown as text only and do not imply equivalence, availability, or shared use.

Catalog navigation

Related Catalog Entries

Other public CAS pages in this catalog. These links support navigation across additional intermediates and do not imply equivalence, availability, or shared use.

CAS 112811-59-3GatifloxacinCAS 121577-32-0Gatifloxacin hydrochlorideCAS 180200-66-2Gatifloxacin sesquihydrateCAS 79660-72-3FleroxacinCAS 405165-61-9Besifloxacin HydrochlorideCAS 106516-24-9SertindoleCAS 13710-19-5Tolfenamic AcidCAS 22916-47-8MiconazoleCAS 100643-71-8DesloratadineCAS 102767-28-2Levetiracetam

RFQ questions for CAS 124858-35-1

What are the key identifiers for Nadifloxacin (CAS 124858-35-1)?

Nadifloxacin is identified by CAS 124858-35-1, with molecular formula C19H21FN2O4, molecular weight 360.4, InChIKey JYJTVFIEFKZWCJ-UHFFFAOYSA-N.

Does CAS 124858-35-1 have reported biological target evidence?

ChEMBL contains qualifying experimental assay evidence associated with 5-hydroxytryptamine receptor 1A, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B, Alpha-1A adrenergic receptor, Alpha-2A adrenergic receptor. These records do not establish therapeutic efficacy or clinical use.

Can I request a COA for CAS 124858-35-1?

Yes. Submit an RFQ and specify COA requirements. Lot-specific COA depends on supplier confirmation.

Can I request supplier SDS for Nadifloxacin?

Yes. Supplier SDS can be requested through the RFQ workflow before handling, storage, shipment, or procurement decisions.

Is CAS 124858-35-1 available for quotation?

Availability, pack size, lead time, and pricing are confirmed through RFQ.

Can MolGraph support bulk sourcing or custom synthesis review?

Submit the CAS number, quantity, purity requirement, and destination country for sourcing review.